REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

Abstract In pancreatic ductal adenocarcinoma (PDAC), the dense desmoplastic stroma and insufficient infiltrating T cells represent a significant barrier to effective immunotherapy. In this phase I, dose-escalation study, previously registered at the Dutch Trial Register and later on at ClinicalTrial...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Songul Kucukcelebi, Freek R. van ‘t Land, Sjoerd H. van der Burg, Ferry A. L. M. Eskens, Marjolein Y. V. Homs, Marcella Willemsen, Anne Onrust-van Schoonhoven, Nina E. M. Rozendaal, Amine Fellah, Disha Vadgama, Miranda Moskie, Koen Bezemer, Michail Doukas, Casper W. F. van Eijck, Ralph Stadhouders, Judith de Vos-Geelen, Aniek E. van Diepen, Ilona Enninga, Rob Meijer, Sumeet V. Ambarkhane, Peter Ellmark, Joachim G. J. V. Aerts, Christianne Groeneveldt, Casper H. J. van Eijck
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Nature Portfolio 2025-11-01
Seri Bilgileri:	Nature Communications
Online Erişim:	https://doi.org/10.1038/s41467-025-66092-1
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

Benzer Materyaller